Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

NCT01456585 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma Pancreas

Interventions

OTHER: Gemcitabine
DRUG: CP-870,893

Sponsor

Abramson Cancer Center at Penn Medicine